BNTX
Price
$80.96Alerts
Change
-$0.42 (-0.52%)
Updated
Nov 20 closing price
Capitalization
21.98B
129 days until earnings call
Intraday BUY SELL Signals
FMED
Price
$32.74Alerts
Change
-$0.02 (-0.06%)
Updated
Nov 12 closing price
Net Assets
30.3M
Intraday BUY SELL Signals
Interact to see
Advertisement

BNTX vs FMED

BNTX vs FMED Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BNTX vs. FMED commentary
Nov 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNTX is a Hold and FMED is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BNTX with price predictions
Nov 20, 2026

BNTX sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for BNTX moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNTX as a result. In 73 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for BNTX turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 36 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for BNTX entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTX advanced for three days, in 180 of 264 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

BNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.238) is normal, around the industry mean (3.596). P/E Ratio (-13.042) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.046) is also within normal values, averaging (9.158). Dividend Yield (0.097) settles around the average of (131.631) among similar stocks. P/S Ratio (7.764) is also within normal values, averaging (443.347).

The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. BNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for FMED with price predictions
Nov 20, 2026

FMED's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for FMED turned positive on November 09, 2026. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in 29 of 33 cases over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on FMED as a result. In 49 of 59 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

FMED moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for FMED crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in 171 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 124 of 143 cases where FMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

FMED broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

FUNDAMENTALS RATINGS
BNTX: Fundamental Ratings
BNTX
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
12
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
93
PRICE GROWTH RATING
1..100
73
P/E GROWTH RATING
1..100
41
SEASONALITY SCORE
1..100
39

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BNTXFMED
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 24 days ago
68%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 10 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
COMPARISON
Comparison
Nov 22, 2026
Stock price -- (BNTX: $80.96)
Brand notoriety:
Market capitalization --

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BNTX’s FA Score shows that 1 FA rating(s) are green while .

  • BNTX’s FA Score: 1 green, 4 red.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BNTX’s TA Score shows that 4 TA indicator(s) are bullish.

  • BNTX’s TA Score: 4 bullish, 5 bearish.

Price Growth

BNTX (@Biotechnology) experienced а -5.42% price change this weekfor the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

Reported Earning Dates

BNTX is expected to report earnings on Mar 30, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BNTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BNTX has been loosely correlated with MRNA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTX
1D Price
Change %
BNTX100%
-0.52%
MRNA - BNTX
60%
Loosely correlated
-2.17%
CRSP - BNTX
49%
Loosely correlated
+0.44%
NVAX - BNTX
45%
Loosely correlated
-3.24%
AXON - BNTX
43%
Loosely correlated
-5.16%
MRVI - BNTX
43%
Loosely correlated
-2.92%
More

FMED and

Correlation & Price change

A.I.dvisor indicates that over the last year, FMED has been loosely correlated with BNTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if FMED jumps, then BNTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FMED
1D Price
Change %
FMED100%
N/A
BNTX - FMED
49%
Loosely correlated
-0.52%
VRTX - FMED
47%
Loosely correlated
-1.08%
IMVT - FMED
46%
Loosely correlated
-2.31%
DYN - FMED
46%
Loosely correlated
-3.31%
KROS - FMED
45%
Loosely correlated
-2.72%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MSS1.100.43
+63.45%
Maison Solutions Inc
EPAC36.36-1.34
-3.55%
Enerpac Tool Group Corp
BWA46.95-2.40
-4.86%
BorgWarner
STAK1.90-0.13
-6.40%
Stak Inc
RLMD2.62-0.49
-15.76%
Relmada Therapeutics